Aktienanalyse zu Merck & Co Inc (MRK)MRKMerck & Co Inc

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Merck & Co Inc is a good buy right now due to its current price of $145.60 being below the average analyst price target of $165, indicating potential upside. Additionally, the stock has shown a strong year-to-date change of +36.78% and a 1-year change of +69.89%, reflecting solid performance. However, the main risk is the significant insider selling, which has increased by 2945.40% over the last month, indicating potential concerns from insiders about the company's future performance.

21 analysts cover MRK: 11 rate it Buy, 10 Hold and 0 Sell. The average price target is 119.53.